Analysts Issue Rare Sell-Side Caution on TopBuild, AMN Healthcare, Amentum

Wall Street analysts have published downbeat forecasts for TopBuild (BLD), AMN Healthcare (AMN), and Amentum (AMTM), a rare occurrence given potential conflicts with investment banks' advisory businesses. The notes highlight valuation concerns for all three stocks as of January 26, 2026. TopBuild trades at $493.19, or 24.1x forward P/E, against a consensus price target of $488.60. AMN Healthcare trades at $20.49 (27.6x forward P/E) with a $20.86 target. Amentum trades at $35.50 (14.8x forward P/E) with a $36.18 target. The article, from research firm StockStory, positions this against its own model portfolio which it claims has returned 244% over the past five years.